Hypersensitivity reactions to carboplatin and cisplatin in non-small cell lung cancer

Por Randall, J. Michael, Bharne, Anjali A., Bazhenova, Lyudmila A.
Publicado em 2013

Oral 1.01: Phase II trial of amrubicin in patients with previously treated advanced thymic malignancies

Por Wakelee, Heather A., Padda, Sukhmani K., Burns, Matthew, Spittler, A. J., Riess, Jonathan W., San Pedro-Salcedo, Melanie, Ramchandran, Kavitha J., Gubens, Matthew A., Neal, Joel W., Loehrer, Patrick J.
Publicado no J Thorac Dis (2015)

Amlodipine in hypertension: a first-line agent with efficacy for improving blood pressure and patient outcomes

Por Fares, Hassan, DiNicolantonio, James J, O'Keefe, James H, Lavie, Carl J
Publicado no Open Heart (2016)

Dysregulation of the Met pathway in non-small cell lung cancer: implications for drug targeting and resistance

Por Sacco, Joseph J., Clague, Michael J.
Publicado no Transl Lung Cancer Res (2015)

Protocol for a single-centre randomised controlled trial of multimodal periarticular anaesthetic...

Por Wall, P D H, Sprowson, A P, Parsons, N, Parsons, H, Achten, J, Balasubramanian, S, Costa, M L
Publicado no BMJ Open (2015)

Starting the fight in the tumor: expert recommendations for the development of human intratumoral immunotherapy (HIT-IT)

Por Marabelle, A, Andtbacka, R, Harrington, K, Melero, I, Leidner, R, de Baere, T, Robert, C, Ascierto, P A, Baurain, J -F, Imperiale, M, Rahimian, S, Tersago, D, Klumper, E, Hendriks, M, Kumar, R, Stern, M, Öhrling, K, Massacesi, C, Tchakov, I, Tse, A, Douillard, J -Y, Tabernero, J, Haanen, J, Brody, J
Publicado no Ann Oncol (2018)

Effectiveness of chemical pleurodesis in spontaneous pneumothorax recurrence prevention: a systematic review

Por Hallifax, R J, Yousuf, A, Jones, H E, Corcoran, J P, Psallidas, I, Rahman, N M
Publicado no Thorax (2017)

Changes in intraocular pressure in study and fellow eyes in the IVAN trial

Por Foss, Alexander J E, Scott, Lauren J, Rogers, Chris A, Reeves, Barney C, Ghanchi, Faruque, Gibson, Jonathan, Chakravarthy, Usha
Publicado no Br J Ophthalmol (2016)

Comparative experimental subcutaneous glanders and melioidosis in the common marmoset (Callithrix jacchus)

Por Nelson, Michelle, Salguero, Francisco J, Dean, Rachel E, Ngugi, Sarah A, Smither, Sophie J, Atkins, Timothy P, Lever, Mark S
Publicado no Int J Exp Pathol (2014)

Protocol for the Electroencephalography Guidance of Anesthesia to Alleviate Geriatric Syndromes (ENGAGES) study: a pragmatic, randomised clinical trial

Por Wildes, T S, Winter, A C, Maybrier, H R, Mickle, A M, Lenze, E J, Stark, S, Lin, N, Inouye, S K, Schmitt, E M, McKinnon, S L, Muench, M R, Murphy, M R, Upadhyayula, R T, Fritz, B A, Escallier, K E, Apakama, G P, Emmert, D A, Graetz, T J, Stevens, T W, Palanca, B J, Hueneke, R L, Melby, S, Torres, B, Leung, J, Jacobsohn, E, Avidan, M S
Publicado no BMJ Open (2016)

Novel non-AR therapeutic targets in castrate resistant prostate cancer

Por Toren, Paul J., Gleave, Martin E.
Publicado no Transl Androl Urol (2013)

Comparative outcomes of squamous and non-squamous non-small cell lung cancer (NSCLC) patients...

Por McKeage, Mark J, Jameson, Michael B
Publicado em 2010

What can we learn from RELAX-AHF compared to previous AHF trials and what does the future hold?

Por Cannon, Jane A, McKean, Andrew R, Jhund, Pardeep S, McMurray, John J V
Publicado no Open Heart (2015)

Tetracycline compounds with non-antimicrobial organ protective properties: Possible mechanisms of action

Por Griffin, Michael O., Ceballos, Guillermo, Villarreal, Francisco J.
Publicado em 2011

The ALK inhibitor PF-06463922 is effective as a single agent in neuroblastoma driven by expression of ALK and MYCN

Por Guan, J., Tucker, E. R., Wan, H., Chand, D., Danielson, L. S., Ruuth, K., El Wakil, A., Witek, B., Jamin, Y., Umapathy, G., Robinson, S. P., Johnson, T. W., Smeal, T., Martinsson, T., Chesler, L., Palmer, R. H., Hallberg, B.
Publicado no Dis Model Mech (2016)

Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: a phase III, randomised, controlled trial (PALACE 3)

Por Edwards, Christopher J, Blanco, Francisco J, Crowley, Jeffrey, Birbara, Charles A, Jaworski, Janusz, Aelion, Jacob, Stevens, Randall M, Vessey, Adele, Zhan, Xiaojiang, Bird, Paul
Publicado no Ann Rheum Dis (2016)

Targeted therapy for non-small cell lung cancer: current standards and the promise of the future

Por Chan, Bryan A., Hughes, Brett G.M.
Publicado no Transl Lung Cancer Res (2015)

MET inhibitors in combination with other therapies in non-small cell lung cancer

Por Padda, Sukhmani, Neal, Joel W., Wakelee, Heather A.
Publicado no Transl Lung Cancer Res (2012)

Non-Alcoholic Steatohepatitis: Limited Available Treatment Options but Promising Drugs in Development and Recent Progress Towards a Regulatory Approval Pathway

Por Filozof, Claudia, Goldstein, Barry J., Williams, Richard N., Sanyal, Arun
Publicado no Drugs (2015)

Efficacy and toxicity of adjuvant chemotherapy in elderly patients with colorectal cancer: the ACCORE study

Por Lund, C M, Nielsen, D, Dehlendorff, C, Christiansen, A B, Rønholt, F, Johansen, J S, Vistisen, K K
Publicado no ESMO Open (2016)